Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Net Cash Flow data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 117.48% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $193.8 million (up 489.37% YoY), and the FY2025 full-year result was $151.2 million, up 1262.27% from the prior year.
• Net Cash Flow eased to $6.3 million in Q1 2026, from $104.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $135.1 million in Q2 2023 to a low of -$71.9 million in Q1 2022.
• A 5-year average of $9.5 million and a median of -$12.9 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 466.0% in 2025, while the deepest fall reached 7486.15% in 2025.
• Tracing KRYS's Net Cash Flow over 5 years: stood at -$24.5 million in 2022, then surged by 39.62% to -$14.8 million in 2023, then tumbled by 92.97% to -$28.5 million in 2024, then soared by 466.0% to $104.3 million in 2025, then tumbled by 93.92% to $6.3 million in 2026.
• Business Quant data shows KRYS's Net Cash Flow at $6.3 million in Q1 2026, $104.3 million in Q4 2025, and $39.1 million in Q3 2025.